WHO Medicines Prequalification Guidance
Many of the guidance documents approved by the WHO Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) are of significant interest and value for manufacturers. But the ECSPP approval process can be lengthy. To be able to respond promptly to demands for new products or for new formulations of existing products, or to incorporate recent pharmaceutical technology developments in their manufacturing processes, manufacturers often require guidance within a much shorter timeframe.
The WHO Prequalification Team therefore works closely and intensively with pharmaceutical experts to develop guidance, as needed, and promptly. In so doing it both facilitates and eases the technical burden associated with quality medicines manufacturer, and expands the range of appropriate products for meeting treatment needs. Moreover, much of the guidance so developed ― together with feedback from manufacturers and regulators ― forms the basis of guidance documents submitted to ECSPP, thereby also facilitating ECSPP processes.
WHO prequalification guidance documents, application forms and templates are listed below. (Date of issue is given in brackets.) Applicants are also advised to consult these and the guidance documents approved by ECSPP.
Procedural guidance
Guidelines on active pharmaceutical ingredient master file procedure (2008)
Technical guidance
FAQ: Active pharmaceutical ingredient master files (APIMFs) (15 April 2015)
FAQ: Active pharmaceutical ingredient master file (APIMF) amendments (10 October 2022)
FAQ: Active pharmaceutical ingredient micronization (15 April 2019)
Application forms & templates
Application for prequalification of an active pharmaceutical ingredient (API) (11 October 2022)
Model letter of access: active pharmaceutical ingredient master file (APIMF) (14 February 2016)
Articles
A review of API quality deficiencies found in APIMFs submitted to WHO and assessed during a 6-year period (2007-2012) was published in April 2014 in the Journal of Pharmacy & Pharmaceutical Sciences (Vol 17, No. 2). The results of the review are compared to those of similar studies reported by the European Directorate for the Quality of Medicines, the European Medicines Agency and the US Food and Drug Administration. The article can be accessed freely at: https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/21228/16347
Technical guidance
Minimum stability data required at the time of filing a generic product application
Requirements for stability studies of finished pharmaceutical products (FPPs) (29 March 2010)
ICHQ3D and Finished Pharmaceutical Products (FPPs) prequalification procedures (05 December 2019)
Nitrosamine contamination policy for FPP applications (an update) - (15 December 2022)
Application forms & templates
Model letter of requalification (19 October 2016)
Quality information summary (QIS) (1 June 2020)
Quality overall summary: product dossier (QOS-PD) (14 March 2023)
Screening checklist for generic products (13 May 2021)
Variation to a prequalified finished pharmaceutical product (FPP) (15 December 2022)
GENERAL GUIDANCE
Frequent Deficiencies in Bioequivalence Study Protocols
PQT/MED-specific Annotations for the ICH M9 Guideline (24 January 2023)
PQT/MED-specific Annotations for Additional Strength Biowaiver Applications (21 May 2021)
Note on Pediatric Products in PQT Medicines (23 January 2024)
COMPARATOR PRODUCTS
Recommended comparator products: antimalarial medicines (31 October 2023)
Recommended comparator products: anti-tuberculosis medicines (29 May 2024)
Recommended comparator products: influenza-specific antiviral medicines (16 August 2024)
Recommended comparator products: medicines for hepatitis B and C (10 December 2019)
Recommended comparator products: medicines for HIV/AIDS and related diseases (28 November 2024)
Recommended comparator products: neglected tropical disease medicines (24 October 2024)
Recommended comparator products: reproductive health medicines (27 November 2020)
Recommended comparator products: therapeutics against COVID-19 (23 March 2022)
Recommended comparator products: treatment of apnoea in preterm infants (27 November 2024)
Recommended comparator products: treatment of disorders due to use of nicotine (14 August 2023)
STUDY DESIGN
Guidelines for good clinical practice for trials on pharmaceutical products (1995)
Guidance on bioequivalence studies for reproductive health medicines (27 November 2022)
Note on Pediatric Products in PQT Medicines (23 January 2024)
Notes on the design of bioequivalence study: abacavir (14 September 2021)
Notes on the design of bioequivalence study: abacavir/lamivudine (12 August 2024)
Notes on the design of bioequivalence study: abacavir/lamivudine/lopinavir/ritonavir (26 July 2021)
Notes on the design of bioequivalence study: albendazole (29 October 2024)
Notes on the design of bioequivalence study: amodiaquine (23 January 2024)
Notes on the design of bioequivalence study: amodiaquine/artesunate (23 January 2024)
Notes on the design of bioequivalence study: amoxicillin (19 September 2024)
Notes on the design of bioequivalence study: amphotericin B (liposomal) (05 September 2023)
Notes on the design of bioequivalence study: arpraziquantel (26 June 2024)
Notes on the design of bioequivalence study: artemether/lumefantrine (30 June 2024)
Notes on the design of bioequivalence study: artesunate (rectal) (31 May 2021)
Notes on the design of bioequivalence study: artesunate/mefloquine (23 January 2024)
Notes on the design of bioequivalence study: artesunate/pyronaridine (18 August 2024)
Notes on the design of bioequivalence study: atazanavir/ritonavir (7 July 2024)
Notes on the design of bioequivalence study: azithromycin (16 December 2022)
Notes on the design of bioequivalence study: baloxavir marboxil (16 September 2024)
Notes on the design of bioequivalence study: baricitinib (29 October 2024)
Notes on the design of bioequivalence study: bedaquiline (23 January 2024)
Notes on the design of bioequivalence study: benzathine benzylpenicillin (27 November 2022)
Notes on the design of bioequivalence study: cabotegravir (04 July 2023)
Notes on the design of bioequivalence study: clindamycin (17 February 2024)
Notes on the design of bioequivalence study: clofazimine (14 May 2021)
Notes on the design of bioequivalence study: cycloserine (29 October 2024)
Notes on the design of bioequivalence study: daclatasvir (23 January 2024)
Notes on the Design of Bioequivalence Study: dapivirine (9 March 2024)
Notes on the design of bioequivalence study: darunavir (20 October 2024)
Notes on the design of bioequivalence study: darunavir/ritonavir (20 October 2024)
Notes on the design of bioequivalence study: delamanid (17 September 2024)
Notes on the design of bioequivalence study: desogestrel (27 November 2022)
Notes on the design of bioequivalence study: dexamethasone (14 October 2021)
Notes on the design of bioequivalence study: diethylcarbamazine (29 October 2024)
Notes on the design of bioequivalence study: dihydroartemisinin + piperaquine tetraphosphate (10 August 2024)
Notes on the design of bioequivalence study: dolutegravir (23 January 2024)
Notes on the design of bioequivalence study: efavirenz (20 October 2024)
Notes on the design of bioequivalence study: emtricitabine/tenofovir alafenamide (26 November 2024)
Notes on the design of bioequivalence study: entecavir (14 May 2021)
Notes on the design of bioequivalence study: ethambutol (6 February 2024)
Notes on the design of bioequivalence study: ethambutol/isoniazid/rifampicin (31 May 2021)
Notes on the design of bioequivalence study: ethinylestradiol/desogestrel (2 August 2024)
Notes on the design of bioequivalence study: ethinylestradiol/levonorgestrel (2 August 2024)
Notes on the design of bioequivalence study: ethionamide (14 May 2021)
Notes on the design of bioequivalence study: etonogestrel implant (27 November 2022)
Notes on the design of bioequivalence study: etravirine (6 February 2024)
Notes on the design of bioequivalence study: fexinidazole (02 July 2019)
Notes on the design of bioequivalence study: fluconazole (6 February 2024)
Notes on the design of bioequivalence study: flucytosine (14 October 2021)
Notes on the design of bioequivalence study: gatifloxacin (18 February 2024)
Notes on the design of bioequivalence study: glecaprevir/pibrentasvir (2 August 2024)
Notes on the design of bioequivalence study: isoniazid (23 January 2024)
Notes on the design of bioequivalence study: isoniazid/pyrazinamide/rifampicin (2 August 2024)
Notes on the design of bioequivalence study: isoniazid/rifampicin (2 August 2024)
Notes on the design of bioequivalence study: isoniazid/rifapentine (24 June 2024)
Notes on the design of bioequivalence study: isoniazid/rifapentine/moxifloxacin (29 June 2024)
Notes on the design of bioequivalence study: ivermectin (26 July 2021)
Notes on the design of bioequivalence study: lamivudine (03 July 2019)
Notes on the design of bioequivalence study: lamivudine /abacavir /dolutegravir (30 May 2024)
Notes on the design of bioequivalence study: lamivudine/tenofovir/dolutegravir (6 July 2024)
Notes on the design of bioequivalence study: lamivudine/tenofovir alafenamide (26 November 2024)
Notes on the design of bioequivalence study: lamivudine/tenofovir disoproxil fumarate (30 May 2024)
Notes on the design of bioequivalence study: lamivudine/tenofovir/efavirenz (31 May 2021)
Notes on the design of bioequivalence study: lamivudine/zidovudine (30 June 2024)
Notes on the design of bioequivalence study: ledipasvir (23 January 2023)
Notes on the design of bioequivalence study: lenacapavir sodium (4 November 2024)
Notes on the design of bioequivalence study: levofloxacin (26 July 2021)
Notes on the design of bioequivalence study: levonorgestrel (27 November 2022)
Notes on the design of bioequivalence study: levonorgestrel implant (27 November 2022)
Notes on the design of bioequivalence study: levonorgestrel intra-uterine system (27 November 2022)
Notes on the design of bioequivalence study: linezolid (26 July 2021)
Notes on the design of bioequivalence study: lopinavir/ritonavir (31 May 2021)
Notes on the design of bioequivalence study: mebendazole (09 March 2023)
Notes on the design of bioequivalence study: medroxyprogesterone acetate (27 November 2022)
Notes on the design of bioequivalence study: mefloquine (31 May 2021)
Notes on the design of bioequivalence study: mifepristone (27 November 2022)
Notes on the design of bioequivalence study: miltefosine (31 May 2021)
Notes on the design of bioequivalence study: misoprostol (27 November 2022)
Notes on the design of bioequivalence study: molnupiravir (02 March 2023)
Notes on the design of bioequivalence study: moxidectin (24 October 2024)
Notes on the design of bioequivalence study: moxifloxacin (26 July 2021)
Notes on the design of bioequivalence study: nicotine chewing gum (23 August 2023)
Notes on the design of bioequivalence study: nicotine transdermal patch (23 August 2023)
Notes on the design of bioequivalence study: nirmatrelvir + ritonavir (6 July 2024)
Notes on the design of bioequivalence study: norethisterone (27 November 2022)
Notes on the design of bioequivalence study: norethisterone enanthate (27 November 2022)
Notes on the design of bioequivalence study: norgestrel (27 November 2022)
Notes on the design of bioequivalence study: oseltamivir (26 July 2021)
Notes on the design of bioequivalence study: para-aminosalicylic acid (6 March 2024)
Notes on the design of bioequivalence study: praziquantel (14 May 2021)
Notes on the design of bioequivalence study: pretomanid (31 October 2023)
Notes on the design of bioequivalence study: primaquine (29 March 2021)
Notes on the design of bioequivalence study: procaine benzylpenicillin (27 November 2022)
Notes on the design of bioequivalence study: progesterone vaginal ring (29 November 2022)
Notes on the Design of Bioequivalence Study: protionamide (9 March 2024)
Notes on the design of bioequivalence study: pyrazinamide (6 February 2024)
Notes on the design of bioequivalence study: pyridoxine (6 February 2024)
Notes on the design of bioequivalence study: pyrimethamine/sulfadoxine (24 January 2024)
Notes on the design of bioequivalence study: raltegravir (20 January 2021)
Notes on the design of bioequivalence study: remdesivir (24 March 2022)
Notes on the design of bioequivalence study: ribavirin (13 September 2021)
Notes on the design of bioequivalence study: rifabutin (14 May 2021)
Notes on the design of bioequivalence study: rifampicin (14 May 2021)
Notes on the design of bioequivalence study: rifampicin/clarithromycin (2 August 2024)
Notes on the design of bioequivalence study: rifapentine (24 January 2024)
Notes on the design of bioequivalence study: ritonavir (30 June 2022)
Notes on the design of bioequivalence study: sofosbuvir (24 January 2024)
Notes on the design of bioequivalence study: sofosbuvir/daclatasvir (2 August 2024)
Notes on the design of bioequivalence study: sofosbuvir/ledipasvir (6 July 2024)
Notes on the design of bioequivalence study: sofosbuvir/velpatasvir (31 May 2021)
Notes on the Design of Bioequivalence Study: sulfadiazine (7 March 2024)
Notes on the design of bioequivalence study: sulfamethoxazole/trimethoprim (31 May 2021)
Notes on the design of bioequivalence study: tafenoquine (24 January 2024)
Notes on the design of bioequivalence study: tenofovir disoproxil fumarate (27 April 2023)
Notes on the design of bioequivalence study: terizidone (29 March 2021)
Notes on the design of bioequivalence study: ulipristal acetate (27 November 2022)
Notes on the design of bioequivalence study: valganciclovir (3 April 2024)
Notes on the design of bioequivalence study: velpatasvir (23 January 2023)
Notes on the design of bioequivalence study: zanamivir (13 September 2021)
Notes on the design of bioequivalence study: zidovudine (13 September 2021)
APPLICATION FORMS & TEMPLATES
Application for a biowaiver: additional strength (21 May 2021)
Application for a biowaiver: Biopharmaceutics Classification System (BCS) (21 May 2021)
Application for a biowaiver for zinc products (10 November 2016)
Presentation of bioequivalence trial information ‒ BTIF (13 January 2023)
Guidance documents
Artemisinin derivatives: summary of nonclinical safety data: introductory remarks (24 January 2016)
FAQ: Prequalification of medicines for reproductive health (29 March 2017)
Oxytocin Injection - Clarification of stability data and storage statement requirements
Q&A: Submission of applications for prequalification of magnesium sulfate injection (6 October 2014)
Application form & template
Zinc product: acceptability study summary form (11 November 2016)
Guidance documents
Templates
Annotated labelling template (25 October 2016)
Labelling template (25 October 2016)
Annotated patient information leaflet (PIL) template (24 October 2016)
Patient information leaflet (PIL) template (24 October 2016)
Annotated summary of product characteristics (SmPC) template (24 October 2016)
Summary of product characteristics (SmPC) template (24 October 2016)
Guidance document
Application form & template
WHO prequalified quality control laboratory (QCL) annual report on activities (1 October 2016)
Annotated labelling template (25 October 2016)
Annotated patient information leaflet (PIL) template (24 October 2016)
Annotated summary of product characteristics (SmPC) template (24 October 2016)
Application for a biowaiver: additional strength (1 May 2012)
Application for a biowaiver: Biopharmaceutics Classification System (BCS) (21 May 2021)
Application for a biowaiver for zinc products (12 December 2012)
Application for active pharmaceutical ingredient master file (APIMF) procedure (6 April 2020)
Application for prequalification of an active pharmaceutical ingredient (API) (11 October 2022)
Labelling template (25 October 2016)
Model letter of access: active pharmaceutical ingredient master file (APIMF) (14 February 2016)
Model letter of agreement with recipient of technical assistance (13 February 2017)
Model letter of requalification (September 2018)
Patient information leaflet (PIL) template (24 October 2016)
Presentation of bioequivalence trial information form (13 January 2023)
Pre-submission meetings request form (2 November 2017)
Quality information summary (QIS) (1 June 2020)
Quality overall summary: product dossier (QOS-PD) (14 March 2023)
Screening checklist for generic products (13 May 2021)
Summary of product characteristics (SmPC) template (24 October 2016)
Variation to a prequalified finished pharmaceutical product (FPP) (15 December 2022)
WHO prequalified quality control laboratory (QCL) annual report on activities (1 October 2016)
Zinc product: acceptability study summary form (11 November 2016)